title: [Comparison of therapeutic effects of SMANCS (+TAE) and Non-SMANCS/LpTAE].
abstract: Therapeutic effects of SMANCS and LpTAE were evaluated for hepatocellular carcinoma (HCC). Since June 1995, SMANCS has been used in 59 patients for their first treatment. LpTAE had been performed for HCC before introduction of SMANCS in our hospital, and 71 patients treated after 1992 were chosen for comparison with the therapeutic effect of SMANCS. Among the patients treated with SMANCS, complete and partial responses (CR and PR) were obtained in 24 cases (41%) and 17 cases (33%), respectively. SMANCS accompanied by TAE was more effective than SMANCS alone. The effects did not depend on the level of the hepatic arterial branch at which SMANCS was administered. In patients treated with LpTAE, CR and PR were obtained in 12 cases (17%) and 18 cases (25%), respectively. SMANCS was significantly more effective than LpTAE. Because of our short experience with SMANCS, we could only show a two year survival rate. The one- and two-year survival rates for SMANCS were 71% and 57%, respectively. They were not significantly different from those for LpTAE, at 80% and 60%. Despite good results of treatment for HCC, a better prognosis could not be expected by SMANCS in this study. These results may be explained as follows. The evaluating the cause of death within two years after first treatment, hepatic failure was more common in patients treated with SMANCS. After treatment by SMANCS, 11 patients (55%) died from hepatic failure. On the other hand, 4 patients (15%) died from hepatic failure after LpTAE. Although there is no significant difference of Child Pugh score, this may indicate that SMANCS has been used for patients with lesser hepatic reserve and this leads to early deaths in patients treated with SMANCS. However, because of the short experience in this study, further observation is necessary for precise evaluation of clinical efficacy of SMANCS.
authors.affiliation: Division of Gastroenterology, Kyoto Katsura Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Nabeshima
authors.forename: J
authors.initials: J
authors.lastname: Ochi
authors.forename: H
authors.initials: H
authors.lastname: Hikita
authors.forename: H
authors.initials: H
authors.lastname: Nishikawa
authors.forename: T
authors.initials: T
authors.lastname: Ohara
authors.forename: A
authors.initials: A
authors.lastname: Torii
authors.forename: S
authors.initials: S
authors.lastname: Fujita
authors.forename: J
authors.initials: J
authors.lastname: Takeda
authors.forename: K
authors.initials: K
authors.lastname: Miura
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D004621:Embolization, Therapeutic; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008299:Maleic Anhydrides / Q000008:administration & dosage*; D008875:Middle Aged; D011137:Polystyrenes / Q000008:administration & dosage*; D015996:Survival Rate; D009353:Zinostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D007459:Iodized Oil; D009353:Zinostatin